Stockscreener 앱 받기
0.431
7.51%
-0.035
시간 외 거래:
.46
0.029
+6.73%
전일 마감가:
$0.466
열려 있는:
$0.4599
하루 거래량:
193.74K
Relative Volume:
0.50
시가총액:
$11.72M
수익:
-
순이익/손실:
$-29.80M
주가수익비율:
-0.3622
EPS:
-1.19
순현금흐름:
$-25.19M
1주 성능:
-6.87%
1개월 성능:
-9.78%
6개월 성능:
-28.15%
1년 성능:
-49.29%
1일 변동 폭
$0.4251
$0.46
1주일 범위
$0.4251
$0.478
52주 변동 폭
$0.384
$1.94
센세이 바이오테라 Stock (SNSE) Company Profile
명칭
Sensei Biotherapeutics Inc
전화
(240) 243-8000
주소
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
SNSE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
0.431 | 11.72M | 0 | -29.80M | -25.19M | -1.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
센세이 바이오테라 Stock (SNSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-06-29 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2021-03-01 | 개시 | Citigroup | Buy |
| 2021-03-01 | 개시 | Oppenheimer | Outperform |
| 2021-03-01 | 개시 | Piper Sandler | Overweight |
모두보기
센세이 바이오테라 주식(SNSE)의 최신 뉴스
Sensei Biotherapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Sensei Biotherapeutics (SNSE) to Release Quarterly Earnings on Wednesday - Defense World
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock - MSN
A stock that deserves closer examination: Sensei Biotherapeutics Inc (SNSE) - US Post News
Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Manila Times
Biotech Spotlight: Sensei Bio Takes Center Stage at Major Healthcare Conference - StockTitan
Sensei Biotherapeutics, Inc. Appoints Robert Pierce as Chief Scientific Officer; Opens its Boston Office - Marketscreener.com
Sensei Biotherapeutics Inc Shares Rise 25.49% From The Lows – But Will They Continue? - Marketing Sentinel
Biotech Advances Breakthrough Cancer Treatment Results - Streetwise Reports
Sensei Biotherapeutics (NASDAQ:SNSE) Earns Buy Rating from HC Wainwright - Defense World
Sensei Biotherapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Australia
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones - The Manila Times
Sensei Bio's Cancer Drug Shows Promise in Phase 1/2 Trial, Enrolls 45 Patients for VISTA Study - StockTitan
Sensei Biotherapeutics faces Nasdaq delisting risk - Investing.com
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - GlobeNewswire
Sensei Biotherapeutics Q3 2024 Results and Strategic Moves - TipRanks
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Sensei Biotherapeutics Inc. (SNSE) Quarterly 10-Q Report - Quartzy
Sensei Bio Cuts 46% of Workforce, Extends Cash Runway to 2026 Amid Restructuring | SNSE Stock News - StockTitan
Sensei Bio lays off 46% of staff, closes research site to fund phase 2 cancer trial - Fierce Biotech
Sensei Biotherapeutics Inc (SNSE) Quarterly 10-Q Report - Quartz
Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences - GlobeNewswire
3 US Penny Stocks To Monitor In October 2024 - Yahoo Finance Australia
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.01% - MSN
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Up 6% - Defense World
Sensata Technologies Holding plc (NYSE:ST) Stock Holdings Trimmed by Mutual of America Capital Management LLC - Defense World
SeQuent Scientific hits 52-week high, surges nearly 9% in 20 minutes - Business Upturn
SENS Stock on the Rise: A Promising Investment - The InvestChronicle
Oman India Investment Fund sells shares worth Rs 75 cr in Senco Gold - The Economic Times
Latest News | Oman India Investment Fund Sells Shares Worth Rs 75 Cr in Senco Gold - LatestLY
Sensiva Health names Ben Williamson as Chief Executive Officer - WV News
Recent Insider Activity Could Benefit Sensata Technologies Holding Plc (ST) - Knox Daily
Is Seelos Therapeutics Inc (SEEL) worth investing in despite its undervalued state? - US Post News
Federated Hermes Inc. Increases Holdings in Sensata Technologies Holding plc (NYSE:ST) - Defense World
46,650 Shares in Sensata Technologies Holding plc (NYSE:ST) Purchased by Schwerin Boyle Capital Management Inc. - Defense World
Trend Tracker for (ST) - Stock Traders Daily
Benjamin Edwards Inc. Buys 169 Shares of Standex International Co. (NYSE:SXI) - Defense World
Sensei Biotherapeutics names new financial chief - Investing.com India
Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com - Defense World
Sensei Biotherapeutics Appoints New Financial Chief - TipRanks
Are Smart Investors Making the Right Decision? Sensata Technologies Holding Plc (ST) - SETE News
Moors & Cabot Inc. Acquires 8,900 Shares of Sensata Technologies Holding plc (NYSE:ST) - Defense World
Sensei Biotherapeutics names new financial chief By Investing.com - Investing.com South Africa
Sensata Technologies (NYSE:ST) Releases Q3 2024 Earnings Guidance - Defense World
Multibagger Alert: Senco Gold Stock Soars 300% Since IPO – Is More Growth on the Horizon? Analysts Weigh In! - Share Price India News
SYSTM Wealth Solutions LLC Lowers Position in Sensata Technologies Holding plc (NYSE:ST) - Defense World
Closing Bell Recap: Seelos Therapeutics Inc (SEEL) Ends at 0.20, Reflecting a -11.51 Downturn - The Dwinnex
Sensei Biotherapeutics’ SNS-103 shows pH-dependent antitumor efficacy - BioWorld Online
Massachusetts Financial Services Co. MA Sells 444,049 Shares of Sensata Technologies Holding plc (NYSE:ST) - Defense World
센세이 바이오테라 (SNSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):